Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.

Authors :: Moon SM
Yoo IY
Huh HJ
Lee NY
Jhun BW
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 Dec 20; Vol. 64 (1). Date of Electronic Publication: 2019 Dec 20 (Print Publication: 2019).
Publication Year :: 2019
Abstract: We evaluated the efficacy of intermittent azithromycin and ethambutol therapy for noncavitary Mycobacterium avium complex pulmonary disease (MAC-PD). Twenty-nine (76%) of 38 patients achieved sputum culture conversion after 12 months of treatment, and sputum smear positivity was an independent factor for failure to achieve culture conversion (adjusted odds ratio, 26.7; 95% confidence interval, 2.1 to 339.9; P = 0.011). Intermittent azithromycin and ethambutol may be an optional treatment regimen for noncavitary MAC-PD.<br /> (Copyright © 2019 American Society for Microbiology.)

Subjects :: Body Mass Index
Drug Therapy, Combination methods
Female
Humans
Lung Diseases microbiology
Male
Mycobacterium avium-intracellulare Infection drug therapy
Odds Ratio
Treatment Outcome
Antitubercular Agents therapeutic use
Azithromycin therapeutic use
Ethambutol therapeutic use
Mycobacterium avium Complex drug effects
Mycobacterium avium Complex pathogenicity

Full Text Access

Tools